167 results on '"Gutierrez, Alexandra"'
Search Results
2. Mucosal Single-Cell Profiling of Crohn’s-Like Disease of the Pouch Reveals Unique Pathogenesis and Therapeutic Targets
3. The Filming Dilemma: The Potential Speech Cost Presented by Camera Coverage of Defamation Cases.
4. Universities and Digital Skills’ Development in Colombia
5. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
6. Real-World Effectiveness and Safety of Tofacitinib in Crohn’s Disease and IBD-U: A Multicenter Study From the TROPIC Consortium
7. Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis
8. Delivery Outcomes of Pregnant Patients With Inflammatory Bowel Diseases Compared With the General Population and With Women With Other Autoimmune Diseases at a Tertiary Care Center
9. Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort
10. Efficacy, non-target impacts, and other considerations of unregistered fipronil-laced baits being used in multiple invasive ant eradication programs.
11. A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
12. Smoking Interacts With CHRNA5, a Nicotinic Acetylcholine Receptor Subunit Gene, to Influence the Risk of IBD-Related Surgery
13. Mo1508: MASS CYTOMETRY ANALYSIS OF CROHN’S DISEASE-LIKE PHENOTYPE OF THE ILEOANAL POUCH FOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS FOR ULCERATIVE COLITIS
14. Participación e inclusión de las mujeres en la economía digital: universidades y competencias digitales en Italia
15. MASS CYTOMETRY ANALYSIS OF CROHN’S DISEASE-LIKE PHENOTYPE OF THE ILEOANAL POUCH FOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS FOR ULCERATIVE COLITIS
16. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
17. Positioning Therapy for Crohn’s Disease
18. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice
19. DIGITAL TRANSFORMATION AND HIGHER EDUCATION IN COLOMBIA: NEW SKILLS FOR NEW OPPORTUNITIES
20. Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases
21. 772 USTEKINUMAB TREATMENT OF REFRACTORY CELIAC DISEASE: A CASE SERIES
22. Ocular Manifestations of Inflammatory Bowel Disease
23. Tu1806 REAL-WORLD EFFECTIVENESS AND SAFETY OF UPADACITINIB IN ULCERATIVE COLITIS: A MULTICENTER STUDY
24. Effectiveness and Safety of Combining Tofacitinib with a Biologic in Patients with Refractory Inflammatory Bowel Diseases
25. S0897 Efficacy and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases
26. Sa1842 COMPARISON OF MODES OF DELIVERY AND DELIVERY OUTCOMES IN PREGNANT WOMEN WITH INFLAMMATORY BOWEL DISEASE AT A TERTIARY CARE CENTER
27. Tu1899 REAL-WORLD EFFECTIVENESS AND SAFETY OF TOFACITINIB IN CROHN'S DISEASE: A MULTI-CENTER STUDY
28. A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
29. Coordinating Preventive Medicine in Patients With Inflammatory Bowel Disease: Whose Responsibility Is It Anyway?
30. Outcome of Surgical Versus Percutaneous Drainage of Abdominal and Pelvic Abscesses in Crohnʼs Disease
31. Delivery Outcomes of Pregnant Patients With Inflammatory Bowel Diseases Compared With the General Population and With Women With Other Autoimmune Diseases at a Tertiary Care Center.
32. The bicycle grief: in the quest for bike-friendly cities, are snobby cyclists their own worst enemies?
33. Chasing Sally Jewell
34. Adherence to Quality of Care Indicators is Greater in Inflammatory Bowel Disease Dedicated Gastroenterologists
35. Clinical experience of natalizumab in Crohn's disease patients in a restricted distribution program
36. Two Candidates, Same Name: The Odd Case of Alaska's Dan Sullivans
37. Inflammatory Bowel Diseases Dedicated Gastroenterologists Have Greater Adherence to Clinical Care Quality Indicators Than General Gastroenterologists
38. Assessment of Gender and Racial Disparities in Quality of Care Indicators for Inflammatory Bowel Disease
39. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol
40. Considerations in Imaging Among Emergency Department Patients With Inflammatory Bowel Disease
41. Smoking Interacts with CHRNA5, a Nicotine Acetylcholine Receptor Subunit Gene, to Influence the Risk of IBD Related Surgery
42. Tratamiento de rescate en la trombosis aguda del stent intracraneal
43. Areas of hyperdenisty after intra-arterial mechanical thrombectomy in acute ischemic stroke
44. Factors Associated with Vedolizumab Failure
45. Reinduction with Certolizumab Pegol in Patients with Crohnʼs Disease Experiencing Disease Exacerbation
46. Tu2013 Assessing Patient Knowledge of Tobacco's Impact on Disease Course and Medical Efficacy in IBD
47. Tu2014 Integration of a Smoking Cessation Health Counselor Improves Quit Rates Among IBD
48. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice
49. Use of Leo plus as a stent-only therapy in the treatment of fusiform intracranial aneurysms
50. Successful uterine artery embolization for intractable postpartum hemorrhage using a novel embolic agent: ONYX
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.